ARC Medical Devices has assembled a highly motivated, talented, and diverse team to help push towards the company’s goal of entering the human market. ARC is a small company with 12 employees, three of which are C-level management. The team is very close-knit and each member is willing to do whatever is necessary to get the job done. This small-office environment makes ARC an excellent place to work with a start-up mentality. Each ARC team member is hired for their specialized skill-sets which fit together and compliment each other like a puzzle.
Dr. Chris Springate has more than 20 years of successful medical device and drug development experience. Dr. Springate led the development and launch of PERIDAN® Concentrate for ARC Medical Devices, a veterinary device for the reduction of post-surgical adhesions in horses and foals. He participated in the regulatory development, clinical plans, and pre-clinical interactions with the US FDA for PERIDAN® Concentrate for both the veterinary and human markets. Dr. Springate also orchestrated the prosecution of ARC’s first patent family and two additional new patent families for PERIDAN® Concentrate, resulting in issued patents and ongoing patent applications in 35 key commercial territories and the registration of the PERIDAN® trademark in over 30 countries. Prior to ARC, Dr. Springate worked for Angiotech Pharmaceuticals, Inc. where he formulated two drug candidates and three combination products. Three of these candidates completed preclinical studies and progressed into the clinic. One of the combination products, the Taxus® Stent, was clinically approved with annual sales over $1 billion USD worldwide.
Mr. Bruce Hay is a chartered accountant with over 30 years of experience building healthcare companies and guiding them to successful exits. Mr. Hay has been instrumental in raising private equity financing for ARC Pharmaceuticals Inc. and ARC Medical Devices Inc. Prior to ARC, Mr. Hay founded and operated a successful accounting firm in Vancouver for more than 20 years. Mr. Hay co-founded ImmGenics Pharmaceuticals Inc. in 1993 and, as Chief Financial Officer, raised ImmGenics’ initial seed capital and subsequent funds. In 2000, Mr. Hay assisted in the sale of ImmGenics to Abgenix, Inc. for approximately CAD 120 million. Mr. Hay was a director of QLT Phototherapeutics Inc. from 1984 to 1988 and was crucial for raising their first seed capital. He was crucial in raising funds for a number of other early stage companies and serves on the board of directors of a number of public and private companies.